Effect of cumulative intravenous voriconazole dose on renal function in hematological patients

Abstract

Intravenous voriconazole (VRC) is formulated by the incorporation of sulfobutylether--cyclodextrin (SBECD), which may accumulate to adversely affect renal function. However, the effect of long-term use of intravenous VRC on renal function is unclear. Our retrospective analysis of data confirmed that worsening of renal function was significantly associated with a cumulative dose of intravenous VRC (400 mg/kg), suggesting that a higher cumulative dose of intravenous VRC is a risk factor for renal dysfunction.